Together, these studies, summarized in Table 2, demonstrate that systemic delivery of MSCs can attenuate aneurysm expansion, reduce inflammation, inhibit MMP activity, and promote elastin preservation, contributing to overall AAA stabilization. This evidence concerns the gene ELN and triple-A syndrome.